Ph: 02247608
Showing card for Clonidine (DB00575)
Version 2.0
Creation Date 2005-06-13 13:24:05
Update Date 2007-12-13 18:04:59
Primary Accession Number DB00575
Secondary Accession Number APRD00174
Name Clonidine
Drug Type
Small Molecule Approved
Description An alpha-2 adrenergic agonist that crosses the blood-brain barrier. Clonidine acts centrally by reducing sympathetic tone, resulting in a fall in diastolic and systolic blood pressure and a reduction in heart rate. It also acts peripherally, and this peripheral activity may be responsible for the transient increase in blood pressure seen during rapid intravenous administration. (From Martindale, the Extra Pharmacopoeia, 30th ed, p350)
Synonyms
Clonidinum [INN-Latin] Clonidinhydrochlorid Clonidine HCl Clonidin Chlornidinum ST 155BS
Brand Names
Adesipress Catapres Catapres-TTS Catapresan Catapressan Catarpres Catarpresan Clonistada Dixarit Duraclon Duraclont Ipotensium Isoglaucon Tenso-Timelets
Brand Mixtures Combipres 0.1/15 Tab (Chlorthalidone + Clonidine Hydrochloride)
Chemical IUPAC Name N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
Chemical Formula C9H9Cl2N3
Chemical Structure 
CAS Registry Number 4205-90-7
InChi Identifier
InChI=1/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5
H2,(H2,12,13,14)/f/h12,14H
KEGG Drug D00281
KEGG Compound Not Available
PubChem Compound 2803
PubChem Substance 163008
ChEBI ID Not Available
PharmGKB ID PA449051
HET ID Not Applicable
GenBank ID Not Available
Drug ID Number [DIN] 02247608
RxList Link Clonidine
PDRhealth Link Clonidine
Wikipedia Link Clonidine
FDA Label Not Available
Material Safety Data Sheet (MSDS) Click for MSDS (pdf)
Synthesis Reference Zeile et al.; U.S. Pat. 3,202,660(1965)
Average Molecular Weight 230.0939 g/mol
Monoisotopic Molecular Weight 229.0174 g/mol
Melting Point 130°C
Predicted Water Solubility 4.80e-01 mg/mL [ALOGPS]
State Solid
Predicted LogP/Hydrophobicity 2.56 [ALOGPS]
Experimental LogS Not Available
Experimental Caco2 Permeability -4.59 [ADME Research, USCD]
pKa/Isoelectric Point Not Available
Mass Spectrum Not Available
MOL File Image
MOL File Text Click Here for MOL File
SDF File Text Click Here for SDF File
PDB File Calculated Text Click Here for PDB File
PDB File Calculated Image
Isomeric SMILES
C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
Canonical SMILES
C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
Drug Category
Sympatholytics Antihypertensive Agents Analgesics Central Alpha-Agonists Adrenergic alpha-Agonists
AHFS Codes 24:08.16
Indication For the treatment of hypertension and maybe used in prophylaxis of migraine or recurrent vascular headache; Menopausal flushing
Pharmacology Clonidine is an antihypertensive agent and an epidural agent for refractory cancer pain. Similar to guanabenz in mechanism of action, clonidine is used in the treatment of hypertension, opiate and nicotine withdrawal, vascular headaches, diabetic diarrhea, glaucoma, ulcerative colitis, Gilles de la Tourette's syndrome, menopause symptoms, severe pain in cancer patients refractory to opiate agonists, and neuropathic pain and in the diagnosis of pheochromocytoma.
Mechanism of Action Clonidine acts as an agonist at presynaptic alpha(2)-receptors in the nucleus tractus solitarius of the medulla oblongata. Stimulation of these receptors results in the supression of efferent sympathetic pathways and the subsequent decrease in blood pressure and vascular tone in the heart, kidneys, and peripheral vasculature. Clonidine is also a partial agonist at presynaptic alpha(2)-adrenergic receptors of peripheral nerves in vascular smooth muscle.
Absorption Well absorbed following oral administration. Bioavailability following chronic administration is approximately 65%.
Toxicity Oral LD50 is 150 mg/kg in rat and 30 mg/kg in dog. Symptoms of overdose include constriction of pupils of the eye, drowsiness, high blood pressure followed by a drop in pressure, irritability, low body temperature, slowed breathing, slowed heartbeat, slowed reflexes, and weakness.
Protein Binding 20-40%
Biotransformation Hepatic. Metabolized through minor pathways. The major metabolite, p-hydroxyclonidine, is present in concentrations less than 10% of those of unchanged clonidine in urine.
Half Life 12-16 hours
Dosage Forms
Form Route
Tablet Oral
Patient Information Click for Patient Information
Contraindications Click for Contraindications
Interactions Click for Interactions
Drug Interactions
Drug Interaction
Acebutolol Increased hypertension when clonidine stopped
Amitriptyline The tricyclic decreases the effect of clonidine
Amoxapine The tricyclic decreases the effect of clonidine
Atenolol Increased hypertension when clonidine stopped
Betaxolol Increased hypertension when clonidine stopped
Bevantolol Increased hypertension when clonidine stopped
Bisoprolol Increased hypertension when clonidine stopped
Carteolol Increased hypertension when clonidine stopped
Carvedilol Increased hypertension when clonidine stopped
Clomipramine The tricyclic decreases the effect of clonidine
Desipramine The tricyclic decreases the effect of clonidine
Doxepin The tricyclic decreases the effect of clonidine
Imipramine The tricyclic decreases the effect of clonidine
Nortriptyline The tricyclic decreases the effect of clonidine
Esmolol Increased hypertension when clonidine stopped
Labetalol Increased hypertension when clonidine stopped
Metoprolol Increased hypertension when clonidine stopped
Mirtazapine Possible hypertensive crisis
Nadolol Increased hypertension when clonidine stopped
Penbutolol Increased hypertension when clonidine stopped
Pindolol Increased hypertension when clonidine stopped
Practolol Increased hypertension when clonidine stopped
Propranolol Increased hypertension when clonidine stopped
Sotalol Increased hypertension when clonidine stopped
Timolol Increased hypertension when clonidine stopped
Protriptyline The tricyclic decreases the effect of clonidine
Trimipramine The tricyclic decreases the effect of clonidine
Oxprenolol Increased hypertension when clonidine stopped
Food Interactions
Take without regard to meals. Avoid alcohol.
Drug Reference
Wikipedia RxList PDRhealth Drugs.com [Show] Schapiro NA: "Dude, you don't have Tourette's:" Tourette's syndrome, beyond the tics. Pediatr Nurs. 2002 May-Jun;28(3):243-6, 249-53. [PubMed] Hossmann V, Maling TJ, Hamilton CA, Reid JL, Dollery CT: Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther. 1980 Aug;28(2):167-76. [PubMed]
Organisms Affected Humans and other mammals
Phase 1 Metabolizing Enzyme
Cytochrome P450 2D6 (CYP2D6)
Phase 1 Metabolizing Enzyme Sequence > sp|P10635|CP2D6_HUMAN Cytochrome P450 2D6 (EC 1.14.14.1)
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI HEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV FAFLVSPSPYELCAVPR
Phase 1 Metabolizing Enzyme SwissProt ID
Phase 1 Metabolizing Enzyme Gene Name
CYP2D6 Show SNPs
Drug Targets
Drug Target 1 Name Alpha-2A adrenergic receptor
Drug Target 1 Synonyms
Alpha-2A adrenoceptor Alpha-2A adrenoreceptor Alpha-2AAR Alpha-2 adrenergic receptor subtype C10
Drug Target 1 Gene Name ADRA2A
Drug Target 1 Protein Sequence > Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS LNPVIYTIFNHDFRRAFKKILCRGDRKRIV
Drug Target 1 Number of Residues 450
Drug Target 1 Molecular Weight 48957
Drug Target 1 Theoretical pI 10.20
Drug Target 1 GO Classification
Function:
signal transducer activity
receptor activity
transmembrane receptor activity
G-protein coupled receptor activity
rhodopsin-like receptor activity
amine receptor activity
adrenoceptor activity
alpha-adrenergic receptor activity
alpha2-adrenergic receptor activity
receptor activity
transmembrane receptor activity
G-protein coupled receptor activity
rhodopsin-like receptor activity
amine receptor activity
adrenoceptor activity
alpha-adrenergic receptor activity
alpha2-adrenergic receptor activity
Process:
cellular process
cell communication
signal transduction
cell surface receptor linked signal transduction
G-protein coupled receptor protein signaling pathway
cell communication
signal transduction
cell surface receptor linked signal transduction
G-protein coupled receptor protein signaling pathway
Component:
cell
membrane
intrinsic to membrane
integral to membrane
membrane
intrinsic to membrane
integral to membrane
Drug Target 1 General Function Involved in alpha2-adrenergic receptor activity
Drug Target 1 Specific Function Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol
Drug Target 1 Pathway Not Available
Drug Target 1 Reaction Not Available
Drug Target 1 Pfam Domain Function PF00001 7tm_1
Drug Target 1 Signals None
Drug Target 1 Transmembrane Regions
34-59 71-96 107-129 150-173 193-217 375-399 407-430
Drug Target 1 Essentiality Non-Essential
Drug Target 1 GenBank ID Protein 178196
Drug Target 1 SwissProt ID P08913
Drug Target 1 SwissProt Name ADA2A_HUMAN
Drug Target 1 PDB ID 1HOF
Drug Target 1 3D Structure Text Click for PDB File
Drug Target 1 3D Structure Image
Drug Target 1 Cellular Location Membrane; multi-pass membrane protein
Drug Target 1 Gene Sequence > Alpha-2A adrenergic receptor, 1353 bp
ATGGGCTCCCTGCAGCCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGG GGCGGCGCCCGGGCCACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCC GGCCTGCTCATGCTGCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACG AGCCGCGCGCTCAAGGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATC CTGGTGGCCACGCTCGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTAC TTCGGCAAGGCTTGGTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCC ATCGTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAG TACAACCTGAAGCGCACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATC TCGGCCGTCATCTCCTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGC CCGCAGCCGGCCGAGCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCG TGCATCGGCTCCTTCTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTAC CAGATCGCCAAGCGTCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCC GCGCCGCCGGGGGGCACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGC CCGGGGGGCGCAGAGGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCC GCGCCGGCCGGGCCGCGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGAC CACGCCGAGCGGCCTCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAG GCCCGAGCGAGCCAGGTGAAGCCGGGCGACAGCCTGCGCGGCGCGGGCCGGGGGCGACGG GGATCGGGACGCCGGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGC GCTGGCGCGGGCGGGCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATC GGAGTGTTCGTGGTGTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGG TGCTCCGTGCCACGCACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCG TTGAACCCGGTCATCTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATC CTCTGTCGGGGGGACAGGAAGCGGATCGTGTGA
Drug Target 1 GenBank ID Gene M23533
Drug Target 1 GeneCard ID ADRA2A
Drug Target 1 GenAtlas ID ADRA2A
Drug Target 1 HGNC ID 281
Drug Target 1 Chromosome Location Chromosome:10
Drug Target 1 Locus 10q24-q26
Drug Target 1 SNPs Show SNPs
Drug Target 1 General References
Fraser CM, Arakawa S, McCombie WR, Venter JC: Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation. J Biol Chem. 1989 Jul 15;264(20):11754-61. [PubMed] Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ, Regan JW: Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science. 1987 Oct 30;238(4827):650-6. [PubMed] Guyer CA, Horstman DA, Wilson AL, Clark JD, Cragoe EJ Jr, Limbird LE: Cloning, sequencing, and expression of the gene encoding the porcine alpha 2-adrenergic receptor. Allosteric modulation by Na+, H+, and amiloride analogs. J Biol Chem. 1990 Oct 5;265(28):17307-17. [PubMed] Chhajlani V, Rangel N, Uhlen S, Wikberg JE: Identification of an additional gene belonging to the alpha 2 adrenergic receptor family in the human genome by PCR. FEBS Lett. 1991 Mar 25;280(2):241-4. [PubMed] Suryanarayana S, Daunt DA, Von Zastrow M, Kobilka BK: A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists. J Biol Chem. 1991 Aug 15;266(23):15488-92. [PubMed] Wang CD, Buck MA, Fraser CM: Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol. 1991 Aug;40(2):168-79. [PubMed] Chung DA, Zuiderweg ER, Fowler CB, Soyer OS, Mosberg HI, Neubig RR: NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix. Biochemistry. 2002 Mar 19;41(11):3596-604. [PubMed]
Drug Target 1 - Drug References
Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL: alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002 Jan;300(1):282-90. [PubMed] Wang XM, Zhang ZJ, Bains R, Mokha SS: Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002 Jul;98(1-2):27-35. [PubMed] Lavand'homme PM, Ma W, De Kock M, Eisenach JC: Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology. 2002 Oct;97(4):972-80. [PubMed] Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M: Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol. 2004 Feb 6;485(1-3):193-6. [PubMed] Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2004 Aug 23;497(2):161-71. [PubMed]
Drug Target 2 Name Substance-K receptor
Drug Target 2 Synonyms
SKR Neurokinin A receptor NK-2 receptor NK-2R Tachykinin receptor 2
Drug Target 2 Gene Name TACR2
Drug Target 2 Protein Sequence > Substance-K receptor
MGTCDIVTEANISSGPESNTTGITAFSMPSWQLALWATAYLALVLVAVTGNAIVIWIILA HRRMRTVTNYFIVNLALADLCMAAFNAAFNFVYASHNIWYFGRAFCYFQNLFPITAMFVS IYSMTAIAADRYMAIVHPFQPRLSAPSTKAVIAGIWLVALALASPQCFYSTVTMDQGATK CVVAWPEDSGGKTLLLYHLVVIALIYFLPLAVMFVAYSVIGLTLWRRAVPGHQAHGANLR HLQAKKKFVKTMVLVVLTFAICWLPYHLYFILGSFQEDIYCHKFIQQVYLALFWLAMSST MYNPIIYCCLNHRFRSGFRLAFRCCPWVTPTKEDKLELTPTTSLSTRVNRCHTKETLFMA GDTAPSEATSGEAGRPQDGSGLWFGYGLLAPTKTHVEI
Drug Target 2 Number of Residues 398
Drug Target 2 Molecular Weight 44440
Drug Target 2 Theoretical pI 8.74
Drug Target 2 GO Classification
Function:
peptide receptor activity, G-protein coupled
neuropeptide receptor activity
tachykinin receptor activity
signal transducer activity
receptor activity
transmembrane receptor activity
G-protein coupled receptor activity
rhodopsin-like receptor activity
neuropeptide receptor activity
tachykinin receptor activity
signal transducer activity
receptor activity
transmembrane receptor activity
G-protein coupled receptor activity
rhodopsin-like receptor activity
Process:
cellular process
cell communication
signal transduction
cell surface receptor linked signal transduction
G-protein coupled receptor protein signaling pathway
cell communication
signal transduction
cell surface receptor linked signal transduction
G-protein coupled receptor protein signaling pathway
Component:
plasma membrane
cell
membrane
intrinsic to membrane
integral to membrane
cell
membrane
intrinsic to membrane
integral to membrane
Drug Target 2 General Function Not Available
Drug Target 2 Specific Function This is a receptor for the tachykinin neuropeptide substance K (neurokinin A). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system
Drug Target 2 Pathway Not Available
Drug Target 2 Reaction Not Available
Drug Target 2 Pfam Domain Function PF00001 7tm_1
Drug Target 2 Signals None
Drug Target 2 Transmembrane Regions
33-56 70-90 108-129 150-170 197-218 252-272 291-310
Drug Target 2 Essentiality Non-Essential
Drug Target 2 GenBank ID Protein 189135
Drug Target 2 SwissProt ID P21452
Drug Target 2 SwissProt Name NK2R_HUMAN
Drug Target 2 PDB ID Not Available
Drug Target 2 3D Structure Text Not Available
Drug Target 2 3D Structure Image Not Available
Drug Target 2 Cellular Location Membrane
Drug Target 2 Gene Sequence > Substance-K receptor, 1197 bp
ATGGGGACCTGTGACATTGTGACTGAAGCCAATATCTCATCTGGCCCTGAGAGCAACACC ACGGGCATCACAGCCTTCTCCATGCCCAGCTGGCAGCTGGCACTGTGGGCACCAGCCTAC CTGGCCCTGGTGCTGGTGGCCGTGACGGGTAATGCCATCGTCATCTGGATCATCCTGGCC CATCGGAGGATGCGCACAGTCACCAACTACTTCATCGTCAATCTGGCGCTGGCTGACCTC TGCATGGCTGCCTTCAATGCCGCCTTCAACTTTGTCTATGCCAGCCACAACATCTGGTAC TTTGGCCGTGCCTTCTGCTACTTCCAGAACCTCTTCCCCATCACAGCCATGTTTGTCAGC ATCTACTCCATGACCGCCATTGCTGCCGACAGGTACATGGCCATCGTCCACCCCTTCCAG CCTCGGCTTTCAGCTCCCAGCACCAAGGCGGTTATTGCTGGCATCTGGCTGGTGGCTCTC GCCCTGGCCTCCCCTCAGTGCTTCTACTCCACCGTCACCATGGACCAGGGTGCCACCAAG TGCGTGGTGGCCTGGCCCGAAGACAGCGGGGGCAAGACGCTCCTCCTGTACCACCTCGTG GTGATCGCCCTCATCTACTTCCTGCCGCTCGCGGTGATGTTTGTAGCCTACAGCGTCATC GGCCTCACGCTCTGGAGGCGCGCAGTGCCCGGACATCAGGCGCACGGTGCCAACCTCCGC CATCTGCAGGCCAAGAAGAAGTTTGTGAAGACCATGGTGCTGGTGGTGCTGACGTTTGCC ATCTGCTGGCTGCCCTACCACCTCTACTTCATCCTGGGCAGCTTCCAGGAGGACATCTAC TGCCACAAGTTCATCCAGCAAGTCTACCTGGCACTCTTCTGGTTGGCCATGAGCTCTACC ATGTACAATCCCATCATCTACTGCTGTCTCAACCACAGGTTTCGCTCTGGGTTCCGGCTT GCCTTCCGCTGCTGCCCATGGGTCACACCCACCAAGGAAGATAAGCTCGAGCTGACTCCC ACGACCTCCCTCTCCACGAGAGTCAACAGGTGTCACACTAAGGAGACTTTGTTCATGGCT GGGGACACAGCCCCCTCCGAGGCTACCAGTGGGGAGGCGGGGCGTCCCCAGGATGGATCA GGGCTATGGTTTGGGTATGGTTTGCTTGCCCCCACCAAAACTCATGTTGAAATTTGA
Drug Target 2 GenBank ID Gene M57414
Drug Target 2 GeneCard ID TACR2
Drug Target 2 GenAtlas ID TACR2
Drug Target 2 HGNC ID 11527
Drug Target 2 Chromosome Location Chromosome:10
Drug Target 2 Locus 10q11-q21
Drug Target 2 SNPs Show SNPs
Drug Target 2 General References
Gerard NP, Eddy RL Jr, Shows TB, Gerard C: The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of cDNA from tracheal and gastric tissues. J Biol Chem. 1990 Nov 25;265(33):20455-62. [PubMed] Gerard NP, Eddy RL Jr, Shows TB, Gerard C: The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of the cDNA from tracheal and gastric tissues. J Biol Chem. 1991 Jan 15;266(2):1354. [PubMed] Graham A, Hopkins B, Powell SJ, Danks P, Briggs I: Isolation and characterisation of the human lung NK-2 receptor gene using rapid amplification of cDNA ends. Biochem Biophys Res Commun. 1991 May 31;177(1):8-16. [PubMed] Gerard NP, Gerard C: Molecular cloning of the human neurokinin-2 receptor cDNA by polymerase chain reaction and isolation of the gene. Ann N Y Acad Sci. 1991;632:389-90. [PubMed]
Drug Target 2 - Drug References
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed]
You are viewing a mobilized version of this site...
View original page here
